Emerging therapies for NASH - the future is now

Expert Review of Clinical Pharmacology

Volumn 10, Issue 5, 2017, Pages 467-469

  Geier, Andreas ^a   Rau, Monika ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

drug development; elafibranor; NAFLD; NASH; obeticholic acid; therapy

Indexed keywords

NEW DRUG;

EDITORIAL; HUMAN; NONALCOHOLIC FATTY LIVER; DRUG DESIGN; PATHOPHYSIOLOGY;

DRUG DESIGN; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85018687083     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1080/17512433.2017.1305269     Document Type: Editorial

References (17)

1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md). 2016;64(1):73–84.
2. Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology (Baltimore, Md). 2016;64(5):1577–1586.
3. Weiss J, R M, Bantel H, et al. NAFLD CSG. Erste daten zur versorgungssituation von patienten mit nicht alkoholischer fettlebererkrankung (NAFLD) in deutschland–eine umfrage an universitären hepatologischen zentren. Z Gastroenterol. 2015 Jun;53(6):562–567.
4. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97.e10.
5. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2005;41(6):1313–1321.
6. Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology (Baltimore, Md). 2012;56(5):1751–1759.
7. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297–2307.
8. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–1685.
9. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145(3):574–82e1.
10. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT):a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–965.
11. Charles ED, M L, Hompesch M, Luo Y, et al. A phase 1 study of BMS-986036 (Pegylated FGF21) in healthy obese subjects. AASLD Liver Meeting; Boston. October 2016;64(S1):546A. Abstract 1082.
12. Charles ED, Tetri BA, Luo Y, et al. A phase 2 study of BMS-986036 (Pegylated FGF21) in obese adults with type 2 diabetes and a high prevalence of fatty liver. AASLD Liver Meeting; Boston. October 2016;64:17A. Abstract 33.
13. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN):a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–690.
14. Ratziu V, Harrison S, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150(5):1147–1159.e5.
15. Abitbol JL, B P, Junien JL, Metabolic effects and good tolerance of IVA337 a Pan-PPAR agonist in diabetic patients warrant further investigation in NASH. ILC. 2016;Abstract PS105.
16. Sanyal AJ, R V, Harrison S, et al., Cenicriviroc versus placebo for the treatment of nonalcoholic steatohepatitis with liver fibrosis:results from the year 1 primary analysis of the phase 2b CENTAUR study. AASLD Liver Meeting; Boston. 2016; Abstract LB–1.
17. Loomba R, L E, Mantry PS, et al., Charlton MR GS-4497, an inhibitor of apoptosis signal-regulating kinase (ASK1), alone or in combination with simtuzumab for the treatment of nonalcoholic steatohepatitis (NASH):a randomized, phase 2 trial. AASLD Liver Meeting; Boston. 2016; Abstract LB–3.